Finding new and better treatments for psychiatric disorders.

Autor: Paul SM; Karuna Therapeutics, Washington University School of Medicine, St. Louis, MO, USA. spaul@karunatx.com., Potter WZ; Independent Consultant, Philadelphia, PA, USA. wzpottermd@gmail.com.

Publikováno v: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2024 Jan; Vol. 49 (1), pp. 3-9. Date of Electronic Publication: 2023 Aug 15.

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.

Autor: Schindler SE; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA., Petersen KK; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA., Saef B; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA., Tosun D; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA., Shaw LM; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Zetterberg H; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; UK Dementia Research Institute Fluid Biomarkers Laboratory, UK DRI at UCL, London, UK.; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA., Dage JL; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.; Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA., Ferber K; Biogen, Biomarkers Group, Cambridge, Massachusetts, USA., Triana-Baltzer G; Neuroscience Biomarkers, Johnson and Johnson Innovative Medicine, San Diego, California, USA., Du-Cuny L; AbbVie, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany., Li Y; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA., Coomaraswamy J; Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Baratta M; Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Mordashova Y; AbbVie, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany., Saad ZS; Neuroscience Biomarkers, Johnson and Johnson Innovative Medicine, San Diego, California, USA., Raunig DL; Takeda Pharmaceutical Company Ltd., Cambridge, Massachusetts, USA., Ashton NJ; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; Banner Alzheimer's Institute, Phoenix, Arizona, USA.; Banner Sun Health Research Institute, Sun City, Arizona, USA., Meyers EA; Alzheimer's Association, Chicago, Illinois, USA., Rubel CE; Biogen, Biomarkers Group, Cambridge, Massachusetts, USA., Rosenbaugh EG; The Foundation for the National Institutes of Health, North Bethesda, Maryland, USA., Bannon AW; AbbVie, North Chicago, Illinois, USA., Potter WZ; Highly qualified expert, Philadelphia, Pennsylvania, USA.

Publikováno v: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Nov; Vol. 20 (11), pp. 8074-8096. Date of Electronic Publication: 2024 Oct 12.

Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms.

Autor: Daniel DG; Signant Health, Blue Bell, PA, USA.; Bioniche Global Development, LLC, McLean, VA, USA.; George Washington University, Washington, DC, USA., Cohen AS; Louisiana State University, Baton Rouge, LA, USA., Harvey PD; University of Miami, Miami, FL, USA., Velligan DI; University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Potter WZ; Independent Expert, Philadelphia, PA, USA., Horan WP; Karuna-A Bristol Myers Squibb Company, Boston, MA, USA., Moore RC; San Diego State University, San Diego, CA, USA., Marder SR; Semel Institute for Neuroscience at UCLA and the VA Desert Pacific Mental Illness Research, Education and Clinical Center, Los Angeles, CA, USA.

Publikováno v: Schizophrenia bulletin open [Schizophr Bull Open] 2024 Oct 18; Vol. 5 (1), pp. sgae027. Date of Electronic Publication: 2024 Oct 18 (Print Publication: 2024).

Shifting the trajectory of therapeutic development for neurological and psychiatric disorders.

Autor: Krainc D; Davee Department of Neurology, Simpson Querrey Center for Neurogenetics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Martin WJ; Johnson & Johnson Innovative Medicine, San Diego, CA, USA., Casey B; Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA., Jensen FE; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Tishkoff S; Departments of Genetics and Biology, University of Pennsylvania, Philadelphia, PA, USA., Potter WZ; Independent Consultant, Philadelphia, PA, USA., Hyman SE; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2023 Nov; Vol. 15 (720), pp. eadg4775. Date of Electronic Publication: 2023 Nov 01.

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.

Autor: Cecchi M; Cognision, KY, USA. Electronic address: mcecchi@cognision.com., Adachi M; Astellas Pharma, CA, USA., Basile A; Merck & Co., Inc., Kenilworth, NJ, USA., Buhl DL; Takeda Pharmaceuticals, MA, USA., Chadchankar H; Novartis, MA, USA., Christensen S; Lundbeck, Denmark., Christian E; Gilgamesh Pharmaceuticals, NY, USA., Doherty J; Sage Therapeutics, MA, USA., Fadem KC; Cognision, KY, USA., Farley B; Sage Therapeutics, MA, USA., Forman MS; Passage Bio, PA, USA., Honda S; Astellas Pharma, CA, USA., Johannesen J; Sage Therapeutics, MA, USA., Kinon BJ; Cyclerion Therapeutics, MA, USA., Klamer D; Anavex Life Sciences Corp., NY, USA., Marino MJ; Merck & Co., Inc., Kenilworth, NJ, USA., Missling C; Anavex Life Sciences Corp., NY, USA., O'Donnell P; Sage Therapeutics, MA, USA., Piser T; Onsero Therapeutics, MA, USA., Puryear CB; Praxis Precision Medicines, MA, USA., Quirk MC; Sage Therapeutics, MA, USA., Rotte M; Novartis, MA, USA., Sanchez C; Alkermes, MA, USA., Smith DG; Alkermes, MA, USA., Uslaner JM; Merck & Co., Inc., Kenilworth, NJ, USA., Javitt DC; Columbia University, NY, USA., Keefe RSE; VeraSci, NC, USA., Mathalon D; University of California, San Francisco, CA, USA., Potter WZ; Independent Consultant, Philadelphia, PA, USA., Walling DP; CenExel Research, USA., Ereshefsky L; CenExel Research, USA; University of Texas Health Science Center at San Antonio, TX, USA.

Publikováno v: Schizophrenia research [Schizophr Res] 2023 Apr; Vol. 254, pp. 178-189. Date of Electronic Publication: 2023 Mar 13.